| The levels of E2F1 mRNA were lower in malignant breast tissues. They declined further with increasing TNM stage. Results suggest E2F1 is a tumour suppressive gene in human breast cancer. | breast, |
| Enhanced NPM-retinoblastoma tumor suppressor protein (pRB) interaction, leading to the relief of the repressive pRB-E2F1 circuitry and the consequent transcriptional activation of E2F1 and several downstream DNA repair genes. | retinoblastoma, |
| Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients. | kidney, |
| Tumor suppressive function of E2F-1 on PTEN-induced serrated colorectal carcinogenesis | colorectal, |
| Chk2 phosphorylates and activates E2F-1 in response to DNA damage, resulting in apoptosis. This suggests a role for E2F-1 in checkpoint control and tumour suppression. | None |
| study identifies a novel E2F1 gene target and further supports the growing body of evidence that the Rb/E2F1 tumor suppressor pathway is involved in the regulation of the DNA lesion recognition step of nucleotide excision repair. | None |
| reveals a tumor suppressor function of miR-449a/b through regulating Rb/E2F1 activity, and suggests that escape from this regulation through an aberrant epigenetic event contributes to E2F1 deregulation and unrestricted proliferation in human cancer | None |
| Studies indicate that the tumor suppressor E2F1 transcription factor (E2F1) is most relevant for cancer progression and chemoresistance. | None |
| oncogenic activities of E2F1 and E2F3 in ErbB2- or Myc-triggered mammary tumorigenesis, and a tumor suppressor role of E2F2 in Myc-mediated mammary tumorigenesis | None |
| E2F1 in gliomas: a paradigm of oncogene addiction. | glioma, |
| E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt s lymphoma. | lymphoma, |
| miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. | leukemia, |
| E2F1-dependent oncogenic addiction of melanoma cells to MDM2. | skin, |
| Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer. | lung, |
| Indicate a novel oncogenic role of E2F1 by enhancing glycolysis via suppression Sirt6 transcription in bladder and prostate tumor cell lines. | prostate,bladder, |
| E2F1 has a cancer protective role in oncogenic BRAF-activated melanoma cells. | skin, |
| E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. | None |
| E2F4 and E2F1 have similar proliferative properties but different apoptotic and oncogenic properties in vivo. | None |
| Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 | None |
| Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2. | None |